ReviewiScience2026
Current trends, applications, and challenges in three-dimensional bioprinting for cardiovascular disease models and therapies.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide. Although conventional treatments such as surgery and transplantation have improved patient survival, they are subject to major limitations. Three-dimensional (3D) bioprinting presents new opportunities for treating CVDs, with the long-term objective of fabricating functional tissues that faithfully replicate native cardiac structure and key physiological functions, including contractile force, electrical conduction, and mechanical integrity. This review outlines the use of 3D bioprinting in modeling principal cardiac disorders, such as arrhythmias, structural heart defects, myocardial infarction, cardiac fibrosis, and heart failure. It further assesses the utility of bioprinting in developing disease models and advancing clinical therapies for these conditions. Finally, we address the ongoing challenges in implementing bioprinting and cardiac tissue engineering for CVDs and suggest possible avenues for improvement. Future studies should prioritize clinical translation and long-term follow-up to evaluate the durability and viability of bioprinted cardiac tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.